Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring.

Laserna-Mendieta EJ, Casanova MJ, Arias Á, Arias-González L, Majano P, Mate LA, Gordillo-Vélez CH, Jiménez M, Angueira T, Tébar-Romero E, Carrillo-Ramos MJ, Tejero-Bustos MÁ, Gisbert JP, Santander C, Lucendo AJ. Nutrients. 2020 Dec 30;13(1):98. doi: 10.3390/nu13010098. PMID: 33396719

Abstract

A lifelong gluten-free diet (GFD) is the only current treatment for celiac disease (CD), but strict compliance is complicated. Duodenal biopsies are the 'gold standard' method for diagnosing CD, but they are not generally recommended for disease monitoring. We evaluated the sensitivity and specificity of fecal gluten immunogenic peptides (GIPs) to detect duodenal lesions in CD patients on a GFD and compared them with serum anti-tissue transglutaminase (tTG) IgA antibodies. A prospective study was conducted at two tertiary centers in Spain on a consecutive series of adolescents and adults with CD who maintained a long-lasting GFD. Adherence to a GFD and health-related quality of life were scored with validated questionnaires. Mucosal damage graded according to the Marsh-Oberhüber classification (Marsh 1/2/3) was used as the reference standard. Of the 97 patients included, 27 presented duodenal mucosal damage and 70 had normal biopsies (Marsh 0). The sensitivity (33%) and specificity (81%) of GIPs were similar to those provided by the two assays used to measure anti-tTG antibodies. Scores in questionnaires showed no association with GIP, but an association between GIPs and patients' self-reported gluten consumption was found (p = 0.003). GIP displayed low sensitivity but acceptable specificity for the detection of mucosal damage in CD.

Keywords: Marsh–Oberhüber type; anti-tissue transglutaminase antibodies; celiac disease; diagnostic accuracy; gluten immunogenic peptides; gluten-free diet monitoring.